Xiaoman Liu is a clinical pharmacist at the First Affiliated Hospital, Sun Yat-sen University (FAH-SYSU), China. She received her Ph.D. from the niversity of Sydney, Australia. Dr. Liu’s research focuses on pharmacogenetics- and pharmacokinetics-based personalised medicine, with a particular emphasis on immunosuppressive therapy. She is a co-author of the International Pharmaceutical Federation (FIP) consensus on the management of immunosuppressants and has contributed to multiple journal articles and book chapters. The FAH-SYSU pharmacy research team is dedicated to investigating the effects of genetic polymorphisms and pharmacokinetic variability on drug levels, efficacy, and side effects, with the aim of improving the safety and effectiveness of medications for pediatric patients and individuals with immunocompromised conditions.